Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: non-small cell lung cancer (NSCLC)

Lung cancer illustration
June 3, 2025/Cancer/News & Insight

Novel Targeted Treatment for NSCLC Effective Across Multiple Regions and Populations

Treatment assigned FDA review date in June 2025

lung cancer

When Lobectomy Is Out: Selecting Treatment for Stage 1 Non-Small Cell Lung Cancer in High-Risk Patients

Resection, radiotherapy or ablation?

Lung cancer cells
June 5, 2024/Cancer/Research

Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

Monisha Sudarshan, MD

Lung Cancer Study Links Preoperative Factors With Spread Through Air Spaces

Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-CNR-4044611-CQD-Hero-650×450. Dr Chaojpg
October 16, 2023/Cancer/Research

Adding EGFR-Directed Systemic Treatment of Stereotactic Radiosurgery May Improve Control of Brain Metastases in Non-Small Cell Lung Cancer

New review published in Cancers suggests a synergistic benefit

lung cancer
June 28, 2023/Cancer/Research

New Risk Calculator Bests Other Clinical Measures in Predicting Overall Survival of Patients with Non-Small Cell Lung Cancer

Radiomic nomogram helps clinicians assess risk in patients treated with stereotactic body radiation therapy

Lung cancer cells
March 28, 2023/Cancer/Research

Move to Next-Generation Sequencing of Non-Squamous Non-Small Cell Lung Cancer a Life Saver with Minimal Additional Cost

Lack of appropriate testing remains a barrier for patients eligible for targeted treatment

22-CNR-2965300-CQD-Hero-650×450
June 3, 2022/Cancer/Tumor Oncology

Second KRAS Inhibitor Represents Another Standard in Patients with Non-Small-Cell Lung Cancer and KRASG12C Mutation

Emerging treatment option for patients with advanced disease

PrimaryPulmonaryCarcinoid
June 29, 2021/Cancer/Tumor Oncology

Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

Lung cancer cells
October 30, 2020/Cancer/Radiation Oncology

Single-Fraction Stereotactic Body Radiation Therapy Effective for Early Stage Lung Cancer

Largest retrospective study to date confirms randomized trials

BackPage 1 of 2Next

Advertisement

Ad